NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
Overall LLY gets a fundamental rating of 6 out of 10. We evaluated LLY against 198 industry peers in the Pharmaceuticals industry. LLY has an excellent profitability rating, but there are some minor concerns on its financial health. LLY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.42% | ||
ROE | 70.45% | ||
ROIC | 27.17% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 40.25% | ||
PM (TTM) | 22.66% | ||
GM | 81.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.19 | ||
Debt/FCF | N/A | ||
Altman-Z | 7.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.37 | ||
Quick Ratio | 1.06 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 52 | ||
Fwd PE | 23.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 34.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.8% |
715.56
-30.5 (-4.09%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.8% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 52 | ||
Fwd PE | 23.92 | ||
P/S | 13.84 | ||
P/FCF | N/A | ||
P/OCF | 72.8 | ||
P/B | 43.03 | ||
P/tB | 170.35 | ||
EV/EBITDA | 34.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.42% | ||
ROE | 70.45% | ||
ROCE | 33.25% | ||
ROIC | 27.17% | ||
ROICexc | 28.73% | ||
ROICexgc | 36.37% | ||
OM | 40.25% | ||
PM (TTM) | 22.66% | ||
GM | 81.7% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.19 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 1.6 | ||
Cap/Depr | 578.92% | ||
Cap/Sales | 21.61% | ||
Interest Coverage | 250 | ||
Cash Conversion | 43.23% | ||
Profit Quality | N/A | ||
Current Ratio | 1.37 | ||
Quick Ratio | 1.06 | ||
Altman-Z | 7.43 |